Today’s Stock Pick: Buy Can Fin Homes at ₹877 – November 7, 2025

Trump administration announces drug pricing deals With Eli Lilly & Novo Nordisk; GLP-1s cut to $245/Month for Medicare & Medicaid, $350→$250 For DTC; Lilly, Novo Commit To $10B+ U.S. Investments, MFN pricing on future launches

Dow Future (US): 86877, -435.0 points/ -0.92%

Nasdaq Future (US): 25151, -469.0 points/ -1.83%

US Small Cap 2000 Future (US): 2421, -43.0 points/ -1.76%

FTSE Future (UK): 8752, -54.0 points/ -0.55%

DAX Future (Germany): 23779, -344.0 points/ -1.43%

CAC Future (France): 7959, -124.0 points/ -1.53%

Gift Nifty: (India) 25490, -101.0 points/ -0.39%

Symbol: STUDDS

Series: Equity “B Group” 

BSE Code: 544599

ISIN: INE00Q601028

Face Value: Rs 5/-

Issue Price: Rs 585/- per share

* Net profit up 73.34% at ₹1,478 Cr Vs ₹852.6 Cr (YoY)

* Revenue up 24.2% at ₹7,047.5 Cr Vs ₹5,672.7 Cr (YoY)

* EBITDA up 74.7% at ₹2,341.7 Cr Vs ₹1,340.5 Cr (YoY)

* Margin at 33.2% Vs 23.6% (YoY)

(Numbers seen better than market estimates)

6th November 2025

Turnover: (NSE + BSE)

Cash Volume: 114454.44 + 9578.84 Total: 124033.28

F&O Volume: 152166.54 + 74932590.37 Total: 75084756.91

Provisional Cash: Rs in Cr, Only NSE

FII/FPI: NET SELL: -3,263.21

(16,791.16 – 20,054.37)

DII: NET BUY: +5,283.91

(19,418.50 – 14,134.59)

CMP: Rs487; TP: Rs690 (under revision); Rating: BUY\

Consol. Revenue: Rs17.6bn, +5.4% y/y, +3.4% q/q higher than our expectation of Rs17bn. We await product-wise breakup to understand the drivers but expect the beat to be driven from higher than expected casting volumes and tube revenues.\u0009

Consol. EBITDA: Rs2.1bn; +10.5% y/y, -1.1% q/q. EBITDA Margins: 12.2%, +57bps y/y, -56bps q/q. Margins were subpar our expectations due to lower casting and steel segment margins.

\u0009

Consol. Adj. PAT: Rs863mn; +11.1% yoy; -9.3% qoq pressured by weak operating profitability.

Our view: 1. Q2FY26 was a beat on revenue (on better than expected performance in casting and tube division) but below our expectation in terms of profitability. The gross margins were lower than expected despite captive iron ore and correction in coking coal cost which needs clarity.

2. There are several other triggers lined up in the stock like scale up of solar power and start of castings volumes from OLiver and Ford, iron ore mine savings and increased forward integration with specialty steel which keeps us positive on long term story. We await volume details for further clarity on operations. 

* Net Profit: ₹33 cr vs ₹13 cr ↑ 154%

* Revenue: ₹161 cr vs ₹100 cr ↑ 61%

* EBITDA: ₹46.4 cr vs ₹22.75 cr ↑ 104%

* EBITDA Margin: 30.3 % vs 23.1 %

MCX, the country’s largest commodity derivatives exchange, has reported a 28 per cent increase in September quarter net profit at ₹197 crore against ₹154 crore logged in the same period last year, on the back of new product launches and higher bullion prices.

MCX Q2 net up 28% at ₹197 cr

MCX reports a 28% net profit increase to ₹197 crore, driven by new products and rising bullion prices.

The short-term outlook is bullish for Can Fin Homes. The stock has been consolidating now within its broad upmove. Support is in the ₹850-₹848 region. Fresh buyers are likely to come in around this support zone. Moving average indicators are also giving bullish signals. As such a fall below ₹848 is less likely.

Stock to buy today: Can Fin Homes (₹877) – BUY

Buy Can Fin Homes stock at ₹877 with a target of ₹960; bullish outlook backed by technical indicators.